Geron (GERN)
(Delayed Data from NSDQ)
$3.79 USD
+0.23 (6.46%)
Updated Apr 26, 2024 04:00 PM ET
Pre-Market: $3.84 +0.05 (1.32%) 8:08 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
Geron Corporation [GERN]
Reports for Purchase
Showing records 181 - 200 ( 236 total )
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
New Management - New Focus - New Execution - Imetelstat on Track for New Data
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
TO FOCUS ON ONCOLOGY - DISCONTINUES REGENERATIVE MEDICINE PROGRAM
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
TO FOCUS ON ONCOLOGY - DISCONTINUES REGENERATIVE MEDICINE PROGRAM
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
2Q11 UPDATE - DIVERSIFIED PIPELINE REDUCES RISK - 2012 PIVOTAL YEAR
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
2Q11 UPDATE - DIVERSIFIED PIPELINE REDUCES RISK - 2012 PIVOTAL YEAR
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
FIRST PATIENT IN SPINAL CORD TRIAL PASSES 180-DAY SAFETY MARK
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
FIRST PATIENT IN SPINAL CORD TRIAL PASSES 180-DAY SAFETY MARK
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Analyst Day Round 2 - Cell Therapy Programs Highlighted & Development Timelines Outlined
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Analyst Day Round 2 - Cell Therapy Programs Highlighted & Development Timelines Outlined
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.